Regeneron tests COVID-19 antibody therapy in UK’s RECOVERY trial
pharmaphorum
SEPTEMBER 16, 2020
The two antibodies chosen by Regeneron bind to the receptor binding domain of the virus’s spike protein, which it uses to bind with and infect healthy cells. The trial involves many thousands of doctors, nurses, pharmacists, and research administrators at 176 hospitals across the whole of the UK.
Let's personalize your content